ATRC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AtriCure Inc (ATRC) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has shown some positive technical indicators and analyst ratings are bullish, the lack of significant recent news, financial performance data, or strong proprietary trading signals suggests a cautious approach. Additionally, the post-market decline and lack of recent congress or insider trading activity further support a hold recommendation.
The MACD histogram is positive and expanding (0.149), indicating bullish momentum. RSI is neutral at 63.149, and moving averages are converging, suggesting no clear trend. Key resistance levels are at 28.816 and 29.412, with support at 26.887 and 26.291. The stock closed at $27.49, slightly below the first resistance level.
Analysts have a bullish outlook, with Canaccord raising the price target to $55 and Freedom Capital initiating coverage with a $43 target, citing growth potential in the Afib franchise and margin expansion. The BoxX-NoAF trial is progressing faster than expected, which could be a future growth driver.
Post-market price decline of -4.55% indicates potential bearish sentiment. Options data suggests bearish trading sentiment with high put-call ratios. No recent news, congress trading data, or insider activity to provide additional confidence.
No financial data available for analysis.
Analysts are bullish with recent upgrades and price targets of $43 and $55, citing growth potential in the Afib franchise and margin expansion. However, these targets are long-term and may not align with the current price action.
